Clinical trial
GW572016 to Treat Recurrent Malignant Brain Tumors
NCT00107003 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00107003 |
|---|---|
| Title | GW572016 to Treat Recurrent Malignant Brain Tumors |
| Official title | A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS |
| Intervention type | Drug, Procedure |
| Interventions | lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy |
| Enrollment | 9 |
| Start date | Mar 30, 2005 |
| Primary completion | Dec 5, 2007 |
| Completion | Nov 30, 2012 |
| First posted | Apr 4, 2005 |
| Last update posted | Jul 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: